What Happened?
Waltham, MA-based Fractyl-Laboratories Appointed Harith Rajagopalan as Chief Executive Officer
About the Company
At Fractyl, we are focused on improving the health of people with Type 2 diabetes. We`ve created an innovative clinical procedure based on new insights into the root cause of the disease. We are currently engaged in clinical trials designed to prove that our innovative procedure can dramatically improve glucose control and reduce the need for additional medications. Our mission is to set people free from the daily burdens of Type 2 diabetes management, empower physicians with a safe and reliable therapeutic treatment, and lower the tremendous human and financial costs of diabetic complications for patients, hospitals, and payers.
About the Person
Dr. Harith Rajagopalan is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in Chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science. After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women`s Hospital and completed a research fellowship at Harvard Medical School.
Info Source
Press Release
Short Profile